FRANKFURT (Reuters) - Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.
ZURICH (Reuters) - Swiss drugmaker Novartis confirmed 2018 growth targets on Thursday as new Chief Executive Officer Vas Narasimhan said he was encouraged by first-quarter performance by his cancer drugs portfolio and a resurgent Alcon eye care unit.
MEXICO CITY (Reuters) - The head of the International Coffee Organization criticized a U.S. judge's decision requiring cancer warnings on coffee sold in California by Starbucks and other retailers, expressing concern that the push for cancer labels may sp
(Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement t
NEW YORK (Reuters) - A $117 million verdict against Johnson & Johnson and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J's Baby Powder could open a new front for thousands of cases claiming the widely
(Reuters) - Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co's Keytruda failed to meet the main goal in a late-stage study.
(Reuters) - Medicare, the U.S. government healthcare program for the elderly and disabled, will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000,
(Reuters) - Johnson & Johnson and Imerys SA must pay at least $37 million in a lawsuit claiming a man developed cancer due to his exposure to asbestos in talc-based products including Johnson's Baby Powder, a New Jersey state court jury said on Thursday
(Reuters) - Eli Lilly and Co on Wednesday said its drug Cyramza met the main goal of helping patients live longer in a late-stage trial, which tested it as a potential treatment for the most common type of liver cancer.